Today researchers at the CRG are amongst some of the world’s leading scientists in receiving funding from the European Research Council’s Advanced Grants Competition. The grant is dedicated lon...
Read moreAs an approach to personalised medicine, the work proposes the HMCES sensor of DNA damage as a target to treat some of the most aggressive types of lung tumours. The results have been published in PL...
Read moreFlomics Biotech, a startup from the Barcelona Biomedical Research Park (PRBB) operating in the genomics and liquid biopsy fields is excited to announce the launch of its seed investment round of 500.0...
Read moreResearchers from the Experimental Oncology Group at the CNIO have achieved complete remission of 25% of lung tumours caused by the KRAS oncogene in mice by inactivating CDK4 and RAF1, two genes that a...
Read moreThe biopharmaceutical company Ability Pharmaceuticals SL announced today that the full description of the mechanism of action of ABTL0812 has been published in the prestigious Autophagy journal (impac...
Read moreRandomized Phase III Study of Ganetespib, a Heat Shock Protein 90 Inhibitor, With Docetaxel Versus Docetaxel in Advanced Non–Small-Cell Lung Cancer (GALAXY-2)
Read moreDespite early encouraging results, the EGFR inhibitor poziotinib failed to meet its primary endpoint in the phase II ZENITH20 trial. For patients with pre-treated NSCLC with EGFR exon 20 insertion mut...
Read moreThe University of Barcelona (UB) and Hospital Clínic de Barcelona collaborate with Boehringer Ingelheim Inc. to improve the efficiency of nintedanib, an antiangiogenic and antifibrotic drug, for the ...
Read moreOryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical needs, today p...
Read moreThe lab of Juan Valcárcel has been awarded a grant from the UK-based Research Charity Worldwide Cancer Research as well as a PRODUCTE grant, 2018 Knowledge Industry, from the Catalonian Government.
Read moreABTL0812 is administered in combination with carboplatin and paclitaxel. Vall d’Hebron Institute of Oncology (VHIO, Barcelona) and Catalan Institute of Oncology (ICO, L’Hospitalet, Barcelona) lead...
Read moreRoger Gomis’ team, in collaboration with another two groups in IRB Barcelona’s Oncology Programme, reveal in Nature Cell Biology the genes and mechanisms that allow liver metastasis to colonize th...
Read more